Sam Brusco, Associate Editor03.22.22
Haemonetics Corp. has appointed James C. D’Arecca as its new executive VP and chief financial officer (CFO). D’Arecca will begin his position on April 11.
He succeeds William P. Burke, who announced his retirement as the company’s CFO last year. Burke will continue to advise for Haemonetics through June 30.
D’Arecca has almost 30 years of experience in finance leadership and strategy. He was most recently CFO of women’s healthcare firm TherapeuticsMD. Before that, he was senior VP and chief accounting officer of Allergan for almost seven years prior to its May 2020 merger with AbbVie. He also held finance and business development roles at Bausch + Lomb, Mercj, and Schering-Plough.
"James brings to Haemonetics substantial experience in financial leadership for prominent global healthcare organizations," Haemonetics president and CEO Chris Simon told the press. "His expertise will play a significant role in supporting our Company's transformational growth objectives and delivering long-term value for our stakeholders. We are excited to welcome him to Haemonetics to lead our global finance team."
"Haemonetics is recognized and respected for its long history of innovation and industry leadership in improving standards of care. I am excited to help the Company continue to achieve strong results, accelerate growth, and expand its impact throughout the world," said D'Arecca.
He succeeds William P. Burke, who announced his retirement as the company’s CFO last year. Burke will continue to advise for Haemonetics through June 30.
D’Arecca has almost 30 years of experience in finance leadership and strategy. He was most recently CFO of women’s healthcare firm TherapeuticsMD. Before that, he was senior VP and chief accounting officer of Allergan for almost seven years prior to its May 2020 merger with AbbVie. He also held finance and business development roles at Bausch + Lomb, Mercj, and Schering-Plough.
"James brings to Haemonetics substantial experience in financial leadership for prominent global healthcare organizations," Haemonetics president and CEO Chris Simon told the press. "His expertise will play a significant role in supporting our Company's transformational growth objectives and delivering long-term value for our stakeholders. We are excited to welcome him to Haemonetics to lead our global finance team."
"Haemonetics is recognized and respected for its long history of innovation and industry leadership in improving standards of care. I am excited to help the Company continue to achieve strong results, accelerate growth, and expand its impact throughout the world," said D'Arecca.